Convalescent sera rollout for coronavirus patients mired in ‘bad practice’
With both vaccines and therapeutics for the coronavirus months away, both doctors and patients have turned to convalescent sera, the blood of recovered coronavirus patients, as a potentially effective means of fending off the disease. In its rush to make that convalescent sera available, the Food and Drug Administration has decided not to implement strict testing guidelines that would ensure the treatment actually proves effective.
Video Transcript
[NO AUDIO]
